Skip to main content
An official website of the United States government

tafasitamab-cxix

View Patient Information
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Tafasitamab-cxix targets and binds to CD19, thereby depleting and eliminating CD19-expressing B cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:immunoglobulin, anti-(human Cd19 antigen) (human-mus musculus monoclonal MOR00208 heavy chain), disulfide with human-mus musculus monoclonal MOR00208 .kappa.-chain, dimer
tafasitamab
US brand name:Monjuvi
Code name:MOR-00208
MOR00208
MOR208
XmAb5574
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search